NASDAQ:COLL
Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc.'s revenue grew 23.6% in fiscal 2025 to $780.6M while operating margin fell to 23.0%. Free cash flow was $327.6M, 42.0% of revenue, and the diluted share count fell 1.8%.Summary generated from Collegium Pharmaceutical, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$780.6M
Revenue growth+23.6%
Revenue, 5-yr CAGR+20.3%
Gross margin59.3%
Operating margin23.0%
Net margin8.1%
ROICn/a
Return on equity23.7%
Debt / equityn/a
Free cash flow$327.6M
FCF margin42.0%
Share count change−1.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 277 | 464 | 567 | 631 | 781 |
| Operating income | 18 | 33 | 167 | 170 | 180 |
| Net income | 72 | −25 | 48 | 69 | 63 |
| Free cash flow | 102 | 123 | 274 | 203 | 328 |
Recent filings
- 8-KOther events
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-K/AAmended current report
Jun 30, 2026 - 4Insider transaction report
Jun 10, 2026 - 4Insider transaction report
May 20, 2026 - 8-KResults of a shareholder vote
May 15, 2026 - 8-KCompletion of an acquisition or disposition
May 12, 2026